ReviewCurrent problems in cancer
The biology of castration-resistant prostate cancer.
Review in Current problems in cancer. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review.Molecular cancer · 2016Pooled it
- Undifferentiated Castration-Resistant Prostate Cancer Successfully Treated With Carboplatin and Paclitaxel.Case reports in urology · 2026Article
- Azolato-Bridged Dinuclear Platinum(II) Complexes Exhibit Androgen Receptor-Mediated Anti-Prostate Cancer Activity.Inorganic chemistry · 2024Article
- Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 2022.Clinical Medicine Insights. Oncology · 2024Article
- Two calix[4]pyrroles as potential therapeutics for castration-resistant prostate cancer.Investigational new drugs · 2022Article
- Review
- Natural Product-Based Studies for the Management of Castration-Resistant Prostate Cancer: Computational to Clinical Studies.Frontiers in pharmacology · 2021Review
- Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators.Cancer drug resistance (Alhambra, Calif.) · 2021Review
- Article
- The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression.Translational oncology · 2020Article
- Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies.Prostate cancer and prostatic diseases · 2020Review
- Novel Method for Structure-Activity Relationship of Aptamer Sequences for Human Prostate Cancer.ACS omega · 2018Article
- Molecular and cellular mechanisms of castration resistant prostate cancer.Oncology letters · 2018Review
- Selection and characterization of DNA aptamer for metastatic prostate cancer recognition and tissue imaging.Oncotarget · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.